These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 27694501)

  • 1. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
    Ustun C; Arock M; Kluin-Nelemans HC; Reiter A; Sperr WR; George T; Horny HP; Hartmann K; Sotlar K; Damaj G; Hermine O; Verstovsek S; Metcalfe DD; Gotlib J; Akin C; Valent P
    Haematologica; 2016 Oct; 101(10):1133-1143. PubMed ID: 27694501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
    Pullarkat ST; Wu W; Pullarkat V
    Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
    Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
    Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
    Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
    Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.
    Valent P; Akin C; Gleixner KV; Sperr WR; Reiter A; Arock M; Triggiani M
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
    Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
    Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.
    Sotlar K; Cerny-Reiterer S; Petat-Dutter K; Hessel H; Berezowska S; Müllauer L; Valent P; Horny HP
    Mod Pathol; 2011 Apr; 24(4):585-95. PubMed ID: 21186345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
    Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
    Valent P; Akin C; Sperr WR; Horny HP; Arock M; Metcalfe DD; Galli SJ
    Annu Rev Pathol; 2023 Jan; 18():361-386. PubMed ID: 36270293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2010 Mar; 17(2):125-32. PubMed ID: 20075725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonality and molecular pathogenesis of mastocytosis.
    Akin C
    Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.